Devyser launches Devyser HLA Loss: A high-precision NGS assay for post-transplant research

Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of Devyser HLA Loss, a next-generation sequencing (NGS) assay designed exclusively to empower researchers with unprecedented sensitivity and speed in detecting HLA loss in post-transplantation studies. 

With immune escape becoming an increasingly important area of investigation in hematopoietic stem cell transplantation (HSCT) research, Devyser HLA Loss sets a new standard by offering precise, fast, and simple detection of HLA loss in mismatched transplant settings. 

Devyser HLA Loss is engineered for sensitive and accurate detection of HLA loss. Designed to complement existing chimerism assays, Devyser HLA Loss supports laboratories in building a comprehensive understanding of post-transplant immune dynamics. 

Addressing a critical gap in transplantation research 

HLA loss is a known mechanism of relapse in certain mismatched transplant scenarios. However, conventional tools may fall short in detecting such events at low levels. Devyser HLA Loss bridges this gap with precision, providing researchers with a reliable method to study immune escape mechanisms and potential treatment resistance patterns. 

"Our goal with Devyser HLA Loss is to bring unmatched sensitivity and ease-of-use to the research community. This launch marks a significant step forward in enabling translational research that could influence future diagnostic and therapeutic strategies,” said Theis Kipling, CCO, Devyser. 

Devyser HLA Loss is currently available globally as a Research Use Only (RUO) product. For product details, visit: https://devyser.com/kits-and-reagents/devyser-hla-loss. 

For more information, please contact: 
Fredrik Dahl, interim CEO  
E-mail: ir@devyser.com 
Telephone: +46 8 562 158 50 
  
Theis Kipling, CCO 
E-mail: ir@devyser.com  
Telephone: +46 8 562 158 50 

About Devyser  

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.  

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.  

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.  

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.  

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company´s certified adviser is Redeye AB. 

Attachments
Devyser launches Devyser HLA Loss: A high-precision NGS assay for post-transplant research